Clinical Trials Directory

Trials / Completed

CompletedNCT04575350

Reinterpretation of CNV With Unknown Significance: a 5-year Retrospective Analysis

Intérêt de la réinterprétation Des CNV de Signification Inconnue Mis en évidence Par ACPA

Status
Completed
Phase
Study type
Observational
Enrollment
282 (actual)
Sponsor
Central Hospital, Nancy, France · Academic / Other
Sex
All
Age
Healthy volunteers
Accepted

Summary

We aim to assess the usefulness of systematic reinterpretation of CNV of unknown significance. To investigate this question we will study all CNV of unknown significance detected between 2010 and 2017.

Detailed description

Array-CGH is a front-line technique in many genetic indications in both prenatal and postnatal settings. It allows the detection of chromosomal rearrangements (duplication or deletion for example) in routine. The interpretation and classification of these copy number variations or CNVs is essential but complex. It requires a systematic and methodical analysis of the variation in the context of the scientific literature. When these revisions do not meet either pathogenicity or benignity criteria, they are referred to as variation of unknown significance (or VUS). They account for a significant proportion of the revisions up to 75% (Palmer et al., 2013). The detection of VUS does not, in most cases, allow for a diagnosis and often requires the use of other, costly techniques. The human impact may also be significant in the absence of possible genetic counselling (e.g. in the context of a future pregnancy). Reanalysis of an VUS is of major interest for at least two reasons : (1) the first, if it is classified as benign, makes it possible to close the investigation of the variant, to consider other leads without ulterior motives, and to reassure the patient about the absence of pathogenicity of the variant. (2) if the VUS is ultimately pathogenic, this makes it possible to name the disease for the patient, to specify genetic counselling, to avoid further long and costly investigation and possibly to propose treatment. Currently, VUS can be reanalysed by the laboratory at the request of the prescribing physician or possibly another physician. However, no systematic reanalysis procedure is currently in place. Although these variations of unknown meanings are frequent and represent an important issue, to our knowledge, no systematic database study has been carried out. Some similar work has nevertheless been carried out over a shorter period or on an ad hoc basis, showing an interest in this type of approach (Palmer et al., 2014). Indeed, it seems essential to determine the interest of reanalysing such variations in several modes: diagnostic, economic and human.

Conditions

Interventions

TypeNameDescription
GENETICreinterpretation of CNVReinterpretation of CNV of unknown significance

Timeline

Start date
2019-01-01
Primary completion
2020-06-01
Completion
2020-06-01
First posted
2020-10-05
Last updated
2020-10-05

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04575350. Inclusion in this directory is not an endorsement.